Immunotherapeutic Advances for NSCLC
Marco Massafra,1,* Maria Ilenia Passalacqua,1,* Vittorio Gebbia,2,3 Paolo Macrì,4 Chiara Lazzari,5 Vanesa Gregorc,5 Carmelo Buda,1 Giuseppe Altavilla,1 Mariacarmela Santarpia1 1Medical Oncology Unit, Department of Human Pathology “G. Barresi”, University of Messina, Messina, Italy; 2...
Guardado en:
Autores principales: | Massafra M, Passalacqua MI, Gebbia V, Macrì P, Lazzari C, Gregorc V, Buda C, Altavilla G, Santarpia M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d1a2a4f3cf6a46fcb7ce7fb6c3146c5b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual immunological blockade in the treatment of metastatic non-small cell lung cancer: reality and perspectives
por: Denis I. Yudin, et al.
Publicado: (2021) -
Oral reactive capillary hemangiomas induced by SHR-1210 in the treatment of non-small cell lung cancer: a case report and literature review
por: Jinhan Zhou, et al.
Publicado: (2021) -
New targeted treatments for non-small-cell lung cancer – role of nivolumab
por: Zago G, et al.
Publicado: (2016) -
Programmed death-ligand 1 expression and tumor-infiltrating lymphocytes in non-small cell lung cancer: association with clinicopathologic parameters
por: Gaurav Garg, et al.
Publicado: (2021) -
Editorial: New Advances in Non-small Cell Lung Cancer Management: Immune Modulation and Targeted Therapies
por: Thierry Berghmans, et al.
Publicado: (2021)